Summary:
- The article analyzes China's multifaceted approach to gene therapy, highlighting a complex landscape that spans from cutting-edge clinical innovation to regulatory hurdles and ethical debates.
- It details how China is simultaneously advancing domestic research, navigating international collaborations, and grappling with the commercialization of CRISPR and other gene-editing technologies in a rapidly evolving clinical environment.